Quoin files application with FDA to begin trial of QRX003 for rare skin disorder

Mar. 15, 2022 11:13 AM ETQuoin Pharmaceuticals, Ltd. (QNRX)By: Ravikash, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • Quoin Pharmaceuticals (NASDAQ:QNRX) submitted an investigational new drug application to the U.S. Food and Drug Administration to begin clinical trial of topical lotion QRX003 for Netherton Syndrome (NS).
  • NS is a rare genetic disorder characterized by scaling skin, hair anomalies and increased susceptibility to eczema, among other things.
  • The company said daily application of QRX003 could potentially lead to improvement in skin architecture and restoration of the skin’s barrier properties.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.